SAN DIEGO, May 7, 2025 ~ San Diego-based biotech firm, ViroMissile, has been recognized as the Top Cancer Destroying Platform 2025 by "Life Sciences Review" magazine. The company's pioneering approach to cancer treatment with its Intravenously Deliverable Oncolytic Virus (IDOV™) platform has caught the attention of the industry.

ViroMissile's innovative platform aims to provide a universal, single-dose therapy that can effectively target and eliminate various types of cancer. At the core of this breakthrough is a genetically engineered vaccinia virus that selectively infects and destroys cancer cells while simultaneously activating the body's immune response.

Unlike traditional oncolytic viruses that require direct tumor injections, ViroMissile's IDOV™ platform allows for systemic intravenous delivery. This means that the therapeutic virus can reach tumors throughout the body, making it a more efficient and less invasive treatment option.

More on TelAve News

• The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
• Whistleblower Seeks SEC and Shareholder Review of Cogent Communications' 2003 Acquisition of FNSI
• $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
• SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
• New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories

CEO of ViroMissile, Dr. Nanhai George Chen, explains their goal: "Our goal is to develop a broadly applicable therapy that leverages the immune system to combat cancer. By focusing on fundamental characteristics of cancer cells, such as rapid division, we aim to create a treatment effective across multiple cancer types."

Since its launch in 2018, ViroMissile has made significant progress in developing its third-generation oncolytic viruses. Pre-clinical studies in mouse models have shown promising results with a single injection being able to eradicate multiple cancers. Early clinical trials in China have also provided compelling evidence that the virus successfully reaches tumors in human patients. The company plans to conduct further clinical trials in the United States and Australia.

The IDOV™ platform includes several product candidates: IDOV-Safe™ for enhanced safety profiles, IDOV-Immune™ designed to boost immune system activation, IDOV-Stealth™ optimized for improved delivery by evading immune detection, and IDOV-Anti-Angio™ which targets tumor blood vessel formation to inhibit growth.

More on TelAve News

• The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
• Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
• Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
• Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway
• ABM for Good™ Launches First Project with Build Change

ViroMissile's approach addresses a critical challenge in oncology - delivering effective therapies with minimal invasiveness and maximum efficiency. By enabling intravenous administration, the company hopes to overcome limitations associated with localized treatments and offer a more patient-friendly alternative.

The company's lean operational model, combined with strategic investments, has allowed for rapid progress without excessive overhead. This efficiency puts ViroMissile in a strong position to bring its innovative therapies to market swiftly and address unmet needs in cancer treatment.

As ViroMissile continues to advance its clinical programs, the company is actively seeking partnerships and investment to support further development and commercialization efforts. With its promising platform, ViroMissile is at the forefront of a new era in cancer therapy.

For more information on ViroMissile and its IDOV™ platform, please visit www.viromissile.com. Interested parties can also contact Derek Danziger, APR at 619-200-2145 for further inquiries.

---

Show All News | Report Violation